NCT00062751View on ClinicalTrials.gov

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

April 30, 2005

Study Completion Date

October 31, 2009

Conditions
Breast Neoplasms
Interventions
DRUG

Letrozole / Temsirolimus (CCI-779)

Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily

DRUG

Letrozole / Temsirolimus (CCI-779)

Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks

DRUG

Letrozole

Letrozole 2.5 mg daily

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY